ArticlePharmaceutics2022

Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer.

Linette T Oosting et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.